Literature DB >> 22867090

Fixed-dose combination therapy in hypertension: pros.

Stefano Taddei1.   

Abstract

Effective treatment of high blood pressure represents a key strategy for reducing the burden of hypertension-related cardiovascular diseases, mostly myocardial infarction and stroke. Despite these well established concepts, however, hypertension remains poorly controlled, worldwide. In addition, treated hypertensive patients often remain at higher risk compared with the normotensive population, even when a satisfactory blood pressure control is achieved, due to the high or very high added cardiovascular risk profile observed in these patients. An emerging strategy to improve blood pressure control and achieve this unmet target for cardiovascular disease prevention in hypertensive patients is represented by a more extensive use of rational and effective combination therapies with respect to monotherapy. Such an approach has been recently proposed even as first-line strategy in hypertensive patients at high added cardiovascular risk or in those in whom strict blood pressure control is required. Within the possible antihypertensive drug combinations currently available for the clinical management of hypertension, those based on the association of drugs inhibiting the renin-angiotensin system and thiazide diuretics or calcium channel blockers have demonstrated to be effective and safe in lowering both systolic and diastolic blood pressure levels with a good tolerability profile. In addition, these strategies have provided evidence for effective cardiovascular protection compared with conventional antihypertensive therapies. Among the antihypertensive drugs able to counteract the deleterious effects of abnormal activation of the renin-angiotensin system, angiotensin II receptor blockers have demonstrated to provide better tolerability profile and greater cardiovascular protection on hypertension-related organ damage compared with ACE inhibitors in randomized controlled clinical trials, in the presence of similar antihypertensive efficacy and safety. In particular, these drugs are characterized by lower rates of drug-related side effects, better compliance and adherence to prescribed antihypertensive regimens, and use in synergistic and rational combination therapies, all factors that may contribute to improve blood pressure control and reduce discontinuations from antihypertensive therapy in treated hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22867090     DOI: 10.1007/bf03262454

Source DB:  PubMed          Journal:  High Blood Press Cardiovasc Prev        ISSN: 1120-9879


  11 in total

1.  Fixed-dose combinations improve medication compliance: a meta-analysis.

Authors:  Sripal Bangalore; Gayathri Kamalakkannan; Sanobar Parkar; Franz H Messerli
Journal:  Am J Med       Date:  2007-08       Impact factor: 4.965

2.  Blood pressure control according to new guidelines targets in low- to high-risk hypertensives managed in specialist practice.

Authors:  Giuseppe Mancia; Achille C Pessina; Bruno Trimarco; Guido Grassi
Journal:  J Hypertens       Date:  2004-12       Impact factor: 4.844

3.  Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations.

Authors:  Thomas J Bramley; Philip P Gerbino; Brian S Nightengale; Feride Frech-Tamas
Journal:  J Manag Care Pharm       Date:  2006-04

4.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Guy De Backer; Anna Dominiczak; Renata Cifkova; Robert Fagard; Giuseppe Germano; Guido Grassi; Anthony M Heagerty; Sverre E Kjeldsen; Stephane Laurent; Krzysztof Narkiewicz; Luis Ruilope; Andrzej Rynkiewicz; Roland E Schmieder; Harry A J Struijker Boudier; Alberto Zanchetti; Alec Vahanian; John Camm; Raffaele De Caterina; Veronica Dean; Kenneth Dickstein; Gerasimos Filippatos; Christian Funck-Brentano; Irene Hellemans; Steen Dalby Kristensen; Keith McGregor; Udo Sechtem; Sigmund Silber; Michal Tendera; Petr Widimsky; José Luis Zamorano; Serap Erdine; Wolfgang Kiowski; Enrico Agabiti-Rosei; Ettore Ambrosioni; Lars H Lindholm; Margus Viigimaa; Stamatis Adamopoulos; Enrico Agabiti-Rosei; Ettore Ambrosioni; Vicente Bertomeu; Denis Clement; Serap Erdine; Csaba Farsang; Dan Gaita; Gregory Lip; Jean-Michel Mallion; Athanasios J Manolis; Peter M Nilsson; Eoin O'Brien; Piotr Ponikowski; Josep Redon; Frank Ruschitzka; Juan Tamargo; Pieter van Zwieten; Bernard Waeber; Bryan Williams
Journal:  J Hypertens       Date:  2007-06       Impact factor: 4.844

5.  Blood-pressure control in the hypertensive population.

Authors:  G Mancia; R Sega; C Milesi; G Cesana; A Zanchetti
Journal:  Lancet       Date:  1997-02-15       Impact factor: 79.321

Review 6.  Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis.

Authors:  Ajay K Gupta; Shazia Arshad; Neil R Poulter
Journal:  Hypertension       Date:  2009-12-21       Impact factor: 10.190

7.  The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly.

Authors:  M Monane; R L Bohn; J H Gurwitz; R J Glynn; R Levin; J Avorn
Journal:  Am J Hypertens       Date:  1997-07       Impact factor: 2.689

8.  Impact of medication adherence on hospitalization risk and healthcare cost.

Authors:  Michael C Sokol; Kimberly A McGuigan; Robert R Verbrugge; Robert S Epstein
Journal:  Med Care       Date:  2005-06       Impact factor: 2.983

9.  Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents.

Authors:  Philip P Gerbino; Omar Shoheiber
Journal:  Am J Health Syst Pharm       Date:  2007-06       Impact factor: 2.637

10.  Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy.

Authors:  Michael Dickson; Craig A Plauschinat
Journal:  Am J Cardiovasc Drugs       Date:  2008       Impact factor: 3.571

View more
  6 in total

Review 1.  Antihypertensive Combination Treatment: State of the Art.

Authors:  M Burnier
Journal:  Curr Hypertens Rep       Date:  2015-07       Impact factor: 5.369

2.  Current perspectives on combination therapy in the management of hypertension.

Authors:  Samir G Mallat; Houssam S Itani; Bassem Y Tanios
Journal:  Integr Blood Press Control       Date:  2013-06-17

3.  Blood pressure control with a single-pill combination of indapamide sustained-release and amlodipine in patients with hypertension: the EFFICIENT study.

Authors:  Uday Jadhav; Jagdish Hiremath; Deepak J Namjoshi; Vinod K Gujral; Kamlakar K Tripathi; Mohammad Siraj; Paramesh Shamanna; Michel Safar
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

4.  Efficacy of newer versus older antihypertensive drugs in black patients living in sub-Saharan Africa.

Authors:  J R M'Buyamba-Kabangu; B C Anisiuba; M B Ndiaye; D Lemogoum; L Jacobs; C K Ijoma; L Thijs; H J Boombhi; J Kaptue; P M Kolo; J B Mipinda; C E Osakwe; A Odili; B Ezeala-Adikaibe; S Kingue; B A Omotoso; S A Ba; I I Ulasi; J A Staessen
Journal:  J Hum Hypertens       Date:  2013-06-27       Impact factor: 3.012

Review 5.  Phentermine and topiramate for the management of obesity: a review.

Authors:  Gina Cosentino; Ariane O Conrad; Gabriel I Uwaifo
Journal:  Drug Des Devel Ther       Date:  2011-04-05       Impact factor: 4.162

6.  Impact of single-pill combination therapy on adherence, blood pressure control, and clinical outcomes: a rapid evidence assessment of recent literature.

Authors:  Konstantinos Tsioufis; Reinhold Kreutz; Georgia Sykara; Joris van Vugt; Tarek Hassan
Journal:  J Hypertens       Date:  2020-06       Impact factor: 4.776

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.